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Summary 
Background 
Skeletal muscle is the major reservoir of body proteins and it can be affected in 
conditions associated to altered protein turnover and metabolism such as 
cancer. Although severe wasting is seen primarily in patients with advanced 
malignancy, some of them present degree of wasting at the onset of disease. 
Autophagy has been recently described to play a relevant role in muscle 
wasting. 
Materials and Methods 
We performed morphometric studies and immunohistochemical analyses on 
intraoperative rectus abdominis muscle biopsies from 50 consecutive weight 
stable colorectal patients and 25 weight-stable patients operated for non-
inflammatory benign diseases with no clinical signs of myopathies. Biochemical 
and molecular analyses have been performed in order to evaluate protein 
profile, the presence of autophagy induction and their correlation with clinical 
outcome. 
Results 
In cancer patients, we observed a subclinical myopathy characterized by an 
abnormal distribution of myonuclei relocated from the periphery inside the 
myofiber. The percentage of myofibers with abnormally located myonuclei was 
significantly higher in patients compared to controls. Analyses on serum 
samples showed that, in the absence of systemic inflammation, in the 
prevalence of cancer patients the levels of albumin and prealbumin were below 
the normal range and the mean value  was significantly lower compared to that 
detected in controls. Molecular analyses showed an accumulation of p62, a 
typical marker of autophagy induction, significantly higher in cancer patients 
compared to controls. We found an inverse correlation between the number of 
abnormally nucleated myofibers and the presence of lymph node metastasis. 
Cancer relapse was correlated with low serum levels of prealbumin  and high 
levels of p62 in myofibers of cancer patients. 
 
5 
 
Conclusions 
Colorectal cancer patients have a subclinical myopathy characterized by 
myofibers with internally located myonuclei. In the absence of inflammation, 
cancer patients show low levels of prealbumin and albumin as markers of 
altered protein turnover and persistent high levels of p62 in myofibers as 
expression of autophagy induction with an impairment in physiological 
autophagic flux. Up to now our data indicate that skeletal muscle fibers show 
nuclear abnormalities that seems to be associated to a better prognosis, while 
the presence of an altered protein turnover at an early stage of disease, with an 
impairment in the physiological autophagic flux, that could be predictive of 
cancer relapse and onset of cancer cachexia. 
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Riassunto 
Introduzione 
Il muscolo scheletrico rappresenta la principale riserva proteica del corpo e può 
essere compromesso in varie affezioni metaboliche e di alterato turnover 
proteico, quale il cancro. Benchè una severa perdita di massa sia generalmente 
presente in quadri neoplastici avanzati, in alcuni casi può essere già evidente in 
una fase di malattia iniziale. L’autofagia è stata recentemente descritta come 
uno dei possibili fattori responsabili del processo catabolico. 
Materiali e Metodi 
50 pazienti sottoposti ad intervento chirurgico per neoplasia colorettale e 25 
pazienti operati per patologia benigna non infiammatoria, in assenza di segni 
clinici di miopatia, sono stati sottoposti a biopsia muscolare su cui sono state 
eseguite analisi di carattere morfometrico ed istochimico. Sono state, inoltre, 
eseguite analisi biochimiche e molecolari al fine di valutare l’assetto proteico e 
lo stato di attivazione del processo autofagico e la loro correlazione con 
l’outcome clinico dei pazienti. 
Risultati 
Nei pazienti neoplastici abbiamo riscontrato la presenza di una miopatia 
subclinica, caratterizzata dalla presenza di fibre muscolari con un’anomala 
localizzazione del nucleo cellulare al centro della fibra, significativamente 
maggiore rispetto ai controlli. L’analisi dell’assetto proteico ha dimostrato valori 
sierici di albumina e prealbumina significativamente più bassi nei pazienti 
oncologici, mentre l’analisi molecolare ha documentato elevati livelli di p62 nelle 
fibre muscolari dei pazienti affetti da carcinoma colorettale, rispetto ai controlli.  
La valutazione dell’outcome clinico ha dimostrato una correlazione inversa tra la 
percentuale di miofibre anomale e l’insorgenza di metastasi linfonodali, mentre 
bassi livelli sierici di prealbumina ed alti livelli di p62 nelle fibre muscolari sono 
risultati correlati con un aumentato rischio di ripresa di malattia 
Conclusioni 
I pazienti affetti da carcinoma colorettale presentano una miopatia subclinica 
già all’insorgenza della malattia, caratterizzata dalla presenza di fibre con 
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alterata posizione del nucleo nella cellula. In assenza di infiammazione 
sistemica e tissutale, i pazienti oncologici presentano bassi livelli sierici di 
albumina e prealbumina, come espressione di un alterato turnover proteico, 
nonché elevati livelli di p62 nelle fibre muscolari, a dimostrazione 
dell’attivazione del processo autofagico che risulta tuttavia compromesso. Tali 
dati suggeriscono, pertanto, un verosimile ruolo protettivo per le anomalie 
nucleari descritte, mentre un alterato turnover proteico ed una compromissione 
del normale flusso autofagico, in concomitanza dell’insorgenza della neoplasia, 
costituiscono un potenziale fattore predittivo negativo in termini di ripresa di 
malattia ed evoluzione verso uno stato cachettico. 
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INTRODUCTION 
1. Cachexia 
The etymology of the word cachexia points to its association with poor 
prognosis: it is derived from the Greek kakos and hexia—“bad condition” and 
has long been recognised as a key sign in many cancers. It is a multifactorial 
condition which comprises skeletal muscle and adipose tissue loss which may 
be compounded by anorexia, a dysregulated metabolic state with increased 
basal energy expenditure and is resistant to conventional nutritional support. 
The pathophysiological mechanisms have begun to be elucidated and this has 
led to developments in therapeutic avenues [1]. Cachexia correlates with poor 
performance status, poor quality of life, and a high mortality rate in cancer 
patients [2]. In a meta-analysis of studies pertaining to patients with advanced 
cancer and survival of less than 90 days, symptoms including weight loss and 
anorexia correlated with poor prognosis [3]. Loss of greater than 5–10% of 
body weight is usually taken as a defining point for cachexia, although the 
physiological changes may be present long before this cutoff point is reached. 
Furthermore, the degree of weight loss which significantly impacts on prognosis 
or performance has not been defined. A longitudinal study has shown that 2.5 
kg weight change over 6–8 weeks is sufficient to produce significant changes in 
performance status [4]. Death usually occurs when there is 30% weight loss 
[5]. The prominent clinical feature of cachexia is weight loss 
in adults (corrected for fluid retention) or growth failure in children (excluding 
endocrine disorders). Anorexia, inflammation, insulin resistance, and increased 
muscle protein breakdown are frequently associated with cachexia [6]. 
However, there is no clear consensus definition of this common problem in 
cancer patients leading to a poor understanding of the aetiology of the 
condition. Earlier 
definitions of cachexia described “a wasting syndrome involving loss of muscle 
and fat directly caused by tumour factors, or indirectly caused by an aberrant 
host response to tumour presence” [7], however more recent definitions have 
downplayed the importance of fat loss and describe cachexia as “a complex 
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metabolic syndrome associated with underlying illness and characterised by loss 
of muscle with or without loss of fat mass” [6], thus highlighting the unique 
consequences of muscle wasting—the hallmark of cachexia. Without an 
established definition, future studies in this area will be hampered. A recent 
consensus definition has been proposed to include further factors to diagnose 
the cachexia syndrome such as involuntary weight loss, decreased muscle 
mass, anorexia, and biochemical alterations (C-Reactive Protein (CRP), albumin, 
haemoglobin [8]). 
One such study looked at 170 pancreatic cancer patients with weight loss >5% 
and whether a triad of >10% weight loss, low food intake (<1500 kcal/day), 
and systemic inflammation (CRP > 10mg/dL) could better predict adverse 
functional outcome as well as poor prognosis versus weight loss alone [8]. 
When two of three of these criteria were present, (representing 60% of the 
patients) a cohort of patients with adverse function and prognosis were 
identified [8]. 
The prevalence of cachexia is thought to be up to 80% of upper gastrointestinal 
cancer patients and 60% of lung cancer patients at the time of diagnosis [9]. 
There are no clear figures for the estimated prevalence within specific cancer 
cohorts. When the electronic medical records of over 8500 patients with a wide 
variety of malignancies were analysed for the prevalence of cachexia amongst 
the cohort, the proportion varied according to which standard definition was 
used: 2.4% using the World Health Organisation’s International Classification of 
Diseases (ICD) cachexia diagnostic code; 5.5% for the ICD diagnosis of 
cachexia, anorexia, abnormal weight, and feeding difficulties; 6.4% were 
prescribedmegestrol acetate, oxandrolone, somatropin, or dronabinol; 14.7% 
had >5% weight loss [10]. Despite methodological flaws, there was an 
interesting lack of overlap between the different criteria pointing to the 
underdiagnosis of cachexia in clinical practice. 
Decreased muscle strength may help distinguish cachexia from other causes of 
anorexia and fatigue in cancer patients [11]. Decreasedmuscle strength could 
be used as a diagnostic criterion with greater sensitivity and specificity for 
cancer cachexia. Cancer patients who are losing weight and have a systemic 
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inflammatory response have poorer performance status [4]. Until a clear 
definition with well-defined cut-offs emerges, identification and treatment of 
cachectic patients as well as research in the area will remain limited. A new 
consensus definition for diagnostic purposes has been suggested and is 
outlined in Table 1 [6]. 
 
 
Table 1: Diagnostic criteria for cachexia syndrome. 
 
 
2. Pathophysiology of Cachexia 
Pathophysiological changes and clinical consequences of cachexia are 
summarised in Figure 1.  
 
2.1 Metabolic Changes.  
The metabolic changes found in cachexia resemble those of infection rather 
than starvation [12] and are multifactorial and complex. Weight loss of cancer 
cachexia is due to loss of both skeletal muscle and adipose tissue mass, 
whereas weight loss is mainly from adipose tissue stores in starvation [13]. In 
cachexia there is an increase in muscle protein catabolism leading 
to net loss of muscle mass. The ATP ubiquitin-dependent proteolytic pathway is 
the greatest contributor to proteolysis in cachexia [14, 15]. Other proteolytic 
pathways such as lysosomal cathepsins B, H, D, and L [16] and activity of the 
calcium/calpain pathway have also been implicated [17]. Increased intracellular 
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proteolytic activity usually manifests as loss of body weight. This proteolysis has 
been shown to occur even in the absence of weight loss in cancer patients. 
Activation of proteolysis is an early event during tumour growth and it may be 
present for a long time prior to its clinical manifestation. Protein synthesis may 
be increased or unchanged [18]. 
Loss of adipose tissue mass is due to lipolysis [5]. This process is driven by lipid 
mobilising factor (LMF) and tumour (and host) factor zinc-alpha-2 glycoprotein 
which has a direct lipolytic effect and sensitises adipocytes to lipolytic stimuli 
and shows increased expression in cachexia [19]. 
A further compounding factor is the increased resting energy expenditure due 
to the dysregulation of energy metabolism. Cancer patients have a higher 
resting energy expenditure than non-cancer controls [20]. It has been 
speculated that this is due to altered gene expression of mitochondrial 
membrane uncoupling proteins which uncouple respiration from ATP production 
resulting in loss of energy as heat [5]. The metabolic changes seen in cachexia 
are a result of the interplay of tumour factors, host factors, and the interaction 
between the two. 
 
 
Figure 1: Clinical consequences of cancer cachexia. 
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2.2. Tumour Factors. 
 Tumour cells produce both proinflammatory and procachectic factors, which 
stimulate a host inflammatory response [1]. Tumour produced procachectic 
factors include proteolysis-inducing [21] and Lipid-mobilising factors [22]. PIF 
has been identified in the urine of weight losing patients with pancreatic, colon, 
lung, ovarian, breast, and liver cancers [22]. In animals, PIF signals via NFκB 
and STAT3 pathways. Stimulation of these pathways, induces proteolysis in 
muscles via the ubiquitin-proteasome pathway and in hepatocytes, results in 
production of IL-6, IL-8 and CRP. Tumour xenografts expressing human PIF do 
not induce cachexia in mice. Further attempts to correlate PIF levels and 
outcomes have not shown any correlation [23]. Therefore the proposed 
mechanisms of PIF have not yet been validated in humans. Parathyroid 
hormone-related peptide (PTHrP), another tumour-derived circulating factor, is 
associated with higher soluble tumour necrosis factor receptor levels and with 
lower albumin and transferrin levels. Lipid mobilising factor has been found in 
cancer patients losing weight but not in those with stable weight. It is thought 
that LMF sensitises adipocytes to lipolytic stimuli 
by increasing cyclic AMP production [24]. LMF may bind to beta adrenergic 
receptors and causes either increased receptor number or increased G protein 
expression [25].  
 
2.3. Host-Tumour Interaction.  
Inflammatory cytokine production by the tumour microenvironment in response 
to tumour cells may drive the cachexia process. Rodent tumour models display 
increased systemic inflammatory cytokine production, which correlates with the 
amount of weight loss. The murine model of cancer cachexia associated with 
systemic inflammation suggests that there is an interplay between IL-1β and IL-
6 within the tumour microenvironment, which leads to their amplification [26]. 
Reduction of IFN-γ by monoclonal antibody treatment reverses cachexia in the 
Lewis lung carcinoma in mice [27]. Pro-inflammatory cytokines produced 
include TNF-α, IL-1 and IL-6 [1]. It is not certain whether the cytokine 
production is primarily from tumour or host inflammatory cells. It has been 
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hypothesised that either tumour cell production of pro-inflammatory cytokines 
or the host inflammatory cell response to tumour cells is the source of the acute 
phase protein response seen in many malignancies and in cachexia. One study 
of oesophagogastric cancers showed cytokine protein concentrations of IL-1β, 
IL-6 and TNF-α are significantly elevated in tumour tissue. Tumour tissue 
concentrations of IL-1β protein correlated with serum CRP concentrations (r = 
0.31, P = .05; linear regression) and tumours with diffuse or patchy 
inflammatory cellular infiltrate were associated with elevated serum CRP [27]. 
Similarly the production of IL-6 by Peripheral Blood Mononuclear Cells (PBMCs) 
in pancreatic cancer patients induced an acute phase protein response in 
another study [26]. Martignoni et al. have suggested that IL-6-overexpression 
in cachectic pancreatic cancer patients is related to the ability of IL-6 producing 
tumours to sensitise PBMC and induce IL-6 expression in PBMCs [27]. TNF-
alpha and the tumour factor proteolysis-inducing factor are the major 
contenders for skeletal muscle atrophy in cachectic patient. They both increase 
protein degradation through the ubiquitin-proteasome pathway and depress 
protein synthesis through phosphorylation of eukaryotic initiation factor 2 alpha 
[19]. Studies have shown that proteolysis-inducing factor levels correlate with 
the appearance of cachexia, but there is some disagreement regarding a 
correlation between serum levels of TNF-alpha and weight loss. Furthermore, 
only antagonists to proteolysis-inducing factor prevent muscle loss in cancer 
patients, suggesting that tumour factors are the most important.  
 
2.4. Host Response Factors 
2.4.1. Acute Phase Protein Response.  
Systemic changes in response to inflammation denoted the acute phase 
response [28]. Up to 50% of patients with solid epithelial cancers may have an 
elevated acute phase protein response [28]. This acute phase protein response 
(APPR) has been associated with hypermetabolism: in pancreatic cancer 
patients APPR correlated with elevated resting energy expenditure and reduced 
energy intake [29]. Other longitudinal studies have found a poorer prognosis in 
patients displaying this response, independent of weight loss [29]. C-reactive 
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protein (CRP) is the most prevalent method used to assess the magnitude of 
the systemic inflammatory response [28]. 
The modified Glasgow prognostic score (mGPS) (Table 2) combines CRP and 
albumin concentrations to create a simple scoring system which is a prognostic 
factor independent of stage and treatment and predicts survival [28, 29]. 
 
 
 
Table 2: Modified Glasgow Prognostic Score (mGPS): an inflammation- 
based prognostic score [28]. 
 
Raised CRP concentrations at the time of admission to hospital are indicative of 
an increased risk for all-cause mortality; there is a 22.8-fold increase in cancer 
mortality in patients with highly elevated CRP concentrations (>80mg/L) [30]. 
This response appears to be prevalent amongst cancer patients with elevated 
CRP measured in almost 80% of 106 patients with inoperable nonsmall cell lung 
cancer (NSCLC), 40% of whom had >5% weight loss [30]. In patients without 
weight loss, those who displayed evidence of a systemic inflammatory response 
reported more fatigue (P < .05) [30]. In patients with gastro-oesophageal 
cancer, the rate of weight loss correlates with serum concentrations of C-
reactive protein [31]. Elevated CRP levels at the time of diagnosis has been 
found to be a predictor of poor prognosis in pancreatic, lung, melanoma, 
multiple myeloma, lymphoma, ovarian, renal, and gastrointestinal tumours. The 
exact mechanisms linking cachexia, APPR, and poor outcomes is not known. It 
may be that this systemic alteration in protein metabolism drives the proteolysis 
of skeletal muscle to fuel the switch to acute phase reactant production. The 
APPR requires large amounts of essential amino acids: 2.6 g of muscle protein 
must be catabolised to produce 1 g of fibrinogen [32]. 
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2.4.2. Neuroendocrine Factors.  
A number of neuroendocrine factors appear to be dysregulated in the cancer 
state resulting in insulin resistance, reduced anabolic activity, and elevated 
cortisol. This dysregulation may be driven by the systemic inflammatory 
response associated with cancer. 
Inflammatory cytokines such as TNF-α and IL-6 have been implicated in insulin 
resistance [33]. The endogenous production of or response to anabolic growth 
factors in patients may be affected either by the tumour or the host response to 
the tumour and may contribute to cachexia. Testosterone or derivatives have 
been shown to increase protein synthesis and muscle mass. Emerging evidence 
implicates reduction in insulin-like growth factor 1 in cachectic states [34]. 
 
2.5. Anorexia and Cachexia: An Interdependent Relationship? 
Whilst loss of appetite and resultant decrease in energy intake undoubtedly 
contribute to weight loss associated with cancer cachexia, whether anorexia 
occurs by an independent process or is a result of the inflammatory process of 
cachexia is not fully understood. Anorexia itself may have a number of 
components—nausea, altered taste sensation, swallowing difficulties, or 
depression. The failure of aggressive supplementary nutritional regimes to 
reverse weight loss in many patients points to primacy of the cachexia disease 
process [5] and in fact, this disease process may act to establish anorexia. It is 
thought that lack of appetite is secondary to factors produced by the tumour or 
the immune response to the tumour. Specifically, cytokines may inhibit the 
neuropeptide Y pathway ormimic negative feedback action of leptin on the 
hypothalamus, leading to anorexia [35]. In a study of patients with gastro-
oesophageal malignancy (n = 220), 83% of whom had weight loss, multiple 
regression identified dietary intake (estimate of effect: 38%), serum CRP 
concentration (estimate of effect: 34%), and stage of disease (estimate of 
effect: 28%) as independent variables in weight loss in these patients [32]. If 
serum CRP is taken as a proxy measure of systemic inflammation due to cancer 
cachexia, this indicates that weight loss in cancer is not merely due to reduced 
calorie intake. Recently, understanding of the physiologicalmechanisms 
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of appetite regulation has been increasing. There are two sets of neurons within 
the arcuate nucleus of the hypothalamus identified to be involved: the 
melanocortin system and the neuropeptide Y system. Neuropeptide Y stimulates 
appetite on its own or via release of other orexigenic proteins. Neurons which 
release α-melanocyte-stimulating hormone (α-MSH) and signal via 
melanocortin-3 and 4 receptors (MC3R, MC4R) result in decrease in food-
seeking behaviour, increased basal metabolic rate and decreased lean body 
mass [36]. These neurons are constitutively active as mutation in the MC4R 
results in childhood obesity. Agouti-related protein (AgRP) is produced by 
neurons (which also produce neuropeptide Y) and counteracts the action of 
MC4R-stimulating proteins promoting appetite [36]. These “appetite neurons” 
also express receptors for circulating leptin and interleukin-1β (IL-1β) [84], both 
of which downregulate appetite and receptors for ghrelin (the orexigenic 
protein, which increases AgRP) [37]. 
 
3. Consequences 
Cachexia results in a state of active inflammation whereby tumour-derived 
factors and the aberrant host response to these factors result in a catabolic 
state. Whether this catabolic state is the ultimate cause of death in some 
patients is unknown although a substantial proportion of cancer patients die 
with symptoms of advanced cachexia [9]. Cachexia directly impacts overall 
survival, quality of life, and physical activity. 
3.1. Survival. 
 Weight loss has been indicated as an important prognostic factor for cancer 
patients. A classic study by DeWys and colleagues underscores the impact and 
outcome of weight loss in cancer patients [2]. Using retrospective evaluation in 
a multicentre study of more than 3000 patients with different tumour types, 
these researchers reported moderate to severe weight loss in 30% to 70% of 
patients, 
depending on the tumor type. The amount of weight loss depends upon tumor 
site, size, type, and stage. Age and treatment type also play a role. The 
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greatest incidence of weight loss was seen among patients with solid tumours, 
for example, gastric, pancreatic, lung, colorectal, and head and 
neck. Patients with solid tumours are often likely to lose 10% or more of their 
usual body weight. There is a lower risk of weight loss in patients with breast 
and hematological cancers. Within each tumour type, survival times were 
shorter for patients who had experienced weight loss than in those who did not. 
Not only did weight loss predict overall survival, but it also indicated a trend 
towards lower chemotherapy response rates. In more recent studies, similar 
findings of reduced survival have been reported. Buccheri and Ferrigno (2001) 
[38] reported in 388 NSCLC cases that total weight loss was the best indicator 
of prognosis. In ovarian cancer Hess et al. (2007) [39] found a significant 
relationship between weight change and survival—on multivariate analysis the 
risk of 
death increased by 7% for each 5% drop of body weight. In Gastro-
oesophageal cancer Deans and Wigmore (2009) [31] reported that patients 
with the lowest rate of weight loss had a median survival of 30.2 months versus 
7.5 months in those with the highest rate of weight loss. One proposed 
mechanism to explain why patients with weight loss have a poorer survival is 
the increased incidence of complications from surgical, radiotherapeutic, and 
chemotherapeutic treatments. In patients with weight loss: chemotherapy 
doses were lower; they developed more frequent and more severe dose limiting 
toxicity and received, on average, one month less chemotherapy (P < .001 in 
all). Weight loss correlated with shorter failure-free survival, overall survival, 
decreased response, quality of life, and performance status (P < .001 in all). 
Whether reduced survival is due to a more aggressive tumour profile in patients 
with weight loss or due to suboptimal treatment related to weight loss, remains 
unknown. 
3.2. Quality of Life.  
Cachexia contributes substantially to morbidity in cancer patients. It is 
associated with symptoms 
such as fatigue, weakness, poor physical performance, and thus leads to a 
lower self-rated quality of life. Indeed, when the impact of various factors is 
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related to self-rated quality of life scores, the proportion determined by weight 
loss is 30% and by nutritional intake 20%, compared to cancer location (30%), 
disease duration (3%), and stage (1%) [40]. Patients who continue to lose 
weight while receiving palliative chemotherapy have reduced global quality of 
life and performance scores when compared to those whose weight loss 
stabilises . 
3.3. Physical Activity.  
Physical activity has been described as a novel, objective, and robust functional 
outcome measure that is frequently impaired in cachectic states [41]. Activity 
levels are influenced by several conventional quality of life domains. 
Measurement of physical activity has long represented a challenge for 
researchers using timeconsuming and expensive tools such as doubly labelled 
water and indirect calorimetry. However research using these methods has 
revealed that although resting energy expenditure may be elevated in cachectic 
patients, total energy expenditure is reduced because weight-losing cancer 
patients reduce the magnitude of their energy deficit through reductions in 
physical activity. In a more recent study by Dahele et al. (2007) [42] using 
advanced ambulatory pedometer technology, cancer patients receiving palliative 
chemotherapy were shown to spend significantly more time lying and sitting, 
and significantly less time in quiet standing or stepping compared with controls, 
taking on average 43% less steps than healthy controls. It is known that bed 
rest leads to a decrease in skeletal muscle mass in healthy patients, due to 
reduced protein synthesis [43]. Thus, loss of physical function results in 
decreases in performance status, ability to perform activities of daily living, 
decreased social interactions, and alterations in body image, all of which 
manifest as reduced quality of life [44]. Interventions which 
increase physical activity would be anticipated to be highly beneficial. 
Antineoplastic therapies such as surgery, radiotherapy and chemotherapy, may 
also impact on the development of systemic inflammation and particularly may 
impact on swallowing difficulties and anorexia due to nausea [45].
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4. Colorectal Cancer 
4.1 Morphology and Histology of Colon and Rectum 
Approximately 60% of colorectal cancer cases arise in the distal part of colon 
(including splenic flexure, descending colon, sigmoid and rectosigmoid colon 
and rectum) in countries where colonic cancer incidence is high, whereas 
proximal (including cecum, ascending colon, hepatic flexure and transverse 
colon) cases predominate in countries with low incidence [46]. The anatomy of 
colon and rectum are illustrated in Figure 2. 
 
Figure 2: Anatomy of colon and rectum in humans. 
 
It has been suggested that the risk of colorectal cancer conferred by various 
environmental (and genetic) factors is different for proximal and distal tumours. 
Various physiological and histological differences exist between the proximal 
and distal part of a normal colon, which may predispose tumours originating at 
these sites to develop along different pathways. It may be convenient to 
categorize colorectal cancers into either proximal or distal location, but it is 
important to note that this is a simplification of colorectal carcinogenesis, and 
that underlying molecular features are responsible for determining tumour 
phenotype. 
These features may very likely show considerable overlap between right- and 
left-sided colorectal cancers. The principal functions of colon are recovery of 
water and propulsion of solid faeces to the rectum prior 
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to defaecation. The luminal surface of the intestine are composed of a columnar 
epithelial mucosa, with finger-like projections (villi) and glandular invaginations 
(crypts). Mucosa consists mainly of two cells types: the absorptive cells 
recovering water and some salts from the liquid residue of the contents of the 
small intestine, and the mucus-secreting goblet cells lubricating the passage of 
faeces. Goblet cells predominate at the base of the villi, whereas the luminal 
surface is almost entirely lined by columnar 
absorptive cells. The cells of the intestinal epithelium are progressively more 
differentiated as they age and pass along the crypt–villus axis. The rectum is 
the short dilated terminal portion of colon. The rectal mucosa is similar to that 
of colon except from more numerous goblet cells. 
The proximal colon originates from the embryonic midgut and is perfused by 
the superior mesenteric artery, surrounded by a multilayered capillary network, 
whereas the distal colon derives from the hindgut and is served by the inferior 
mesenteric artery, surrounded by a single-layered capillary network. The 
multilayered capillary network in proximal colon is possibly related to the 
greater water absorption and electrolyte transport capacity. The average villi 
length is greater in the distal colon than in the proximal colon. The apoptotic 
index is lower in the right colon compared to the left colonic mucosa [47]. 
Gastrointestinal stem cells undergo multi-potent division to produce the entire 
specialised cell repertoire of the gastrointestinal tract. The numbers and 
location of stem cells in the intestinal crypts and gastric glands have never been 
conclusively proven, and, consequently, the clonal origins of these structures 
under normal circumstances and in neoplasia are clouded issues. Intestinal 
stem cells are primitive cells located in a specialised compartment consisting of 
epithelial and mesenchymal cells and extra-cellular substrates that lack 
expression of any definitive markers of lineage commitment and are therefore 
difficult to define and to characterise morphologically. It is believed that the 
surrounding mesenchymal cells regulate stem cell behaviour through paracrine 
secretion of growth factors and cytokines [48]. The number of stem cells within 
the compartment is believed to be between four and six [48], but the exact 
number has never been conclusively proven and, consequently, is the topic of 
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debate still. It has been postulated that stem cell number may fluctuate 
throughout the crypt cycle and that the stem cell number varies throughout 
different regions of the gastrointestinal tract [49]. Monoclonal intestinal crypts 
have been demonstrated following irradiation, showing that a single multipotent 
surviving stem cell can regenerate an entire crypt, thus confirming the 
hypothesis, that the epithelial cell lineages of the gastrointestinal tract are 
clonal populations derived from a single stem cell, albeit in damaged mucosa. 
No evidence of any crypts with a mixed phenotype was observed in 2260 crypts 
located at the periphery of a patch, indicating that colonic crypts are indeed 
monoclonally derived, which is consistent with results obtained previously [50]. 
However, conflicting data have emerged from different studies, and the 
pathways and mechanisms of gastrointestinal neoplasia are thus far uncertain. 
The turnover of cells in the gastrointestinal tract is high throughout life with the 
differentiating cells shed into the lumen and replaced every 2–7 days under 
normal circumstances. Thus, lifespan of the cells are not sufficient to 
accumulate the mutations necessary for malignant change, why the perpetual 
stem cell is widely believed to be the target of mutational changes. A stem cell 
division can produce one stem cell and one daughter cell (asymmetric division), 
two stem cells by self-replication (symmetric division) or a stem cell loss, where 
both daughter cells go on to differentiate (symmetric division) [51]. 
The majority of divisions are thought to be asymmetric. According to the so-
called immortal strand hypothesis there may be a retention of the template DNA 
strand within the stem cell located in the niche [52], which allows any DNA 
replication errors to pass into the differentiating, shortlived daughter cell 
affording a mechanism of stem cell genome protection [52]. If indeed stem 
cells are the original targets for the mutation(s) required to initiate a neoplasm, 
then whether such a cell acts alone or in cooperation 
with other mutated stem cells becomes important. 
The stem cell compartment is believed to be at the origin of the crypt–villus 
axis. However, as mentioned before the location of the gastrointestinal stem 
cells is debated. Studies by Wright have suggested a location in the mid crypt of 
the ascending colon and in the base of the crypt of the descending colon [53], 
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whereas different observations have been made in other studies. It has been 
suggested that a crypt would be incited to go into fission when it reached a 
threshold size. However, the stem cell number is now thought to be the 
important factor [53]. 
 
4.2 Morphology and Histology of Polyps in Colon and Rectum 
A polyp is defined as a mass that protrudes into the lumen of the colon. Polyps 
may be non-neoplastic or neoplastic. The non-neoplastic polyps are 
hyperplastic, inflammatory, juvenile or hamartomatous and lack dyplastic 
features. Adenomatous polyps are benign neoplasms that, by definition, display 
some dysplasia. The degree of dysplasia may be graded into mild, moderate 
and severe on the basis of cytological and structural features. Adenomatous 
polyps are generally believed to be precursors of most colorectal 
adenocarcinomas, which is supported by epidemiological, genetic and 
pathological studies. Patients with adenomatous polyps have a higher risk of 
colon cancer over the general population and the risk increases if the polyps are 
multiple [54]. 
Neoplastic polyps are histological divided into three sub-groups: tubular 
adenomas, villous adenomas and mixed or tubulo-villous adenomas. The risk of 
malignant transformation is low in tubular adenomas (2-3%) and high in pure 
villous adenomas (15-25%), while the mixed adenomas have an intermediate 
risk of malignant transformation. The risk of developing subsequent cancer is 
generally believed to be higher in patients with polyps larger than 1cm in 
diameter [55]. The initiated polyp may be present and proliferate for 10-15 
years before undergoing malignant transformation [56]. The earliest and 
smallest recognizable histopathological entity may be an aberrant crypt focus 
(ACF). Two types of ACFs have been observed in humans: The common one 
called the hyperplastic or non-dysplastic crypt being a hypercellular crypt with 
normal individual cells which is unlikely to lead to clinically significant lesions, 
and the less common one called dysplastic ACFs, which are believed to be the 
precursors of the adenomas and carcinomas [57]. 
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There are currently two proposed morphological pathways of spontaneous 
development of adenomas, the ‘‘bottom up’’ and the “‘top down’’ pathways 
(illustrated in Figure 3). The gastrointestinal stem cells are important players in 
each of them. In the “bottom-up model” a stem cell situated in the base of the 
crypt acquires mutations in the tumoursuppressor gene adenomatous polyposis 
coli (APC), which thereby impairs the function of the APC protein (a). The 
mutated cell proliferates and produces neoplastic daughter cells, which migrate 
upwards to colonise the entire crypt (b) and form a monocryptal adenoma 
[157]. Further expansion is achieved by crypt fission (c) [158], where crypts 
undergo bifurcation (division into two) followed by longitudinal division, with 
the ultimate formation of two daughter crypts. Thus, this model involves 
monocryptal adenomas, where the dysplastic cells occupy an entire single crypt. 
These lesions are observed to be common in FAP [58]. 
 
 
Figure 3: Top-down or bottom-up growth of colorectal adenomas. Adapted from 
[59] 
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The “top-down model” is based on observations of dysplastic cells only located 
at the luminal surface of the crypts (d), along with migration of adenomatous 
cells from the surface to the base of the crypt (e). In this model an initial stem 
cell mutation is proposed to occur in the epithelial mucosa situated in the intra-
cryptal zone, between two crypt orifices, with subsequent stem cell division 
producing a mutant clone which expands laterally and downwards into the 
crypt, and thereby displacing the normal epithelial cells (f) [59]. Analysis of four 
single-nucleotide polymorphisms (SNP) within the APC gene in tissue from 
sporadic adenomas showed loss of heterogeneity (LOH) of APC in cells in the 
upper portion of the crypts, while no LOH was observed in the histological 
normal crypt bases [59]. Cells towards the top of the crypt display high 
proliferation activity [60]. These observations led to two hypotheses for a top-
down model instead of the conventional bottom-up model: The stem cell could 
be located in the intra-cryptal zone, or if located in the base of the crypt the 
APC mutation in the stem cell would prevent it from a terminal differentiation 
and alter the cell’s migration dynamics, migrate to the luminal surface and 
allowing it to remain in the mucosa before expanding laterally and downwards 
[61]. Both models (‘‘top-down’’ and ‘‘bottom-up’’) may possibly occur. However, 
the bulk of evidence indicates, that the gastrointestinal stem cells are located in 
the base of the crypt [51], with no indication of a stem cell population in the 
intra-cryptal zone, and so the modified top-down hypothesis is proposed; that a 
stem cell in the crypt base acquires a mutation and subsequently migrates to 
the intra-cryptal zone, whereupon it undergoes neoplastic expansion. A crypt 
cycle, the time from a crypt “born” by crypt fission until they divide by crypt 
fission themselves, takes approximately 9-18 years in the human colon [62]. 
Studies on the methylation patterns of adjacent crypts showed significant inter-
crypt variation, both in adjacent crypts and in those up to 15 cm apart, which 
may be a consequence of the time taken for crypts to divide, allowing 
neighbouring crypts to develop different methylation patterns during the 
process [63]. 
Identification of the origins, location, and molecular regulators of the intestinal 
stem cell will provide a clearer understanding of the genetic pathways and cell 
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signaling involved in the neoplastic changes in colorectal carcinogenesis. The 
stepwise pattern of mutational activation of oncogenes and inactivation of 
tumour suppressor genes that causes adenomas to develop to adenocarcinoma 
are called the adenoma–carcinoma sequence. 
 
4.3 The Adenoma-Carcinoma Sequence 
The progression of normal tissue through dysplasia to tumour tissue involves 
numerous steps. It is estimated that a typical colorectal tumour contains at 
least 11,000 genomic alterations. Two distinct pathways have been suggested 
in colorectal carcinogenesis. One involves chromosomal instability, which is 
characterized by allelic losses in chromosome 5q (APC), 17p (p53) and 18q 
(DCC/SMAD4), and the other involves microsatellite instability (MSI). The initial 
mutations in most of the cases occur at the APC tumour-suppressor gene locus 
(5 q21- q22). Loss of APC tumour suppressor gene function is thought to be 
one of the first genetic changes in colorectal adenoma development. APC 
encodes a large multifunctional cytoplasmic protein [64], which is an essential 
component of a “destruction complex” in the Wnt pathway involved in the 
binding and down-regulation of beta-catenin and thereby preventing excessive 
cell proliferation. Additionally, APC are involved in regulation of apoptosis, cell-
cycle progression and chromosomal stability (reviewed in [65]. Hence, the 
importance of the APC protein in a number of different regulatory functions in 
cells in colon means, that mutation in the APC gene alone may be sufficient to 
provide a stem cell with a selective growth advantage by allowing unregulated 
activation of Wnt signalling. Hundreds of specific APC mutations have been 
characterised, and the position of the mutation appears to dictate the severity 
and onset of the hereditary syndrome FAP [66]. Patients with FAP have an 
autosomally dominant inherited germline mutation of APC and are therefore 
susceptible to mutation of the remaining wild-type APC allele [67]. FAP is 
characterized by the presence of hundreds of polyps in the large bowel. These 
arise first in the rectum and distal colon before extending to more proximal 
segments. Close to 100% of FAP individuals will develop colorectal cancer in the 
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distal colon. The mutations and genetic occurrences in the adenoma-carcinoma 
sequence are summarized and illustrated in Figure 4. 
 
 
Figure 4: The possible genetic occurrences in the adenoma-carcinoma 
sequence. 
 
Mutations in APC are found in 63% of sporadic adenomas and up to 80% of 
sporadic colorectal tumours [68]. Mutations in beta-catenin, that prevents the 
breakdown of the protein, can also promote adenoma initiation; however, small 
adenomas with beta-catenin mutations alone do not progress to larger 
adenomas or carcinomas as frequently as adenomas with APC mutations [69]. 
The P53 gene, located on chromosome 17p, is a tumour suppressor gene and is 
frequently lost in colorectal malignancy. The gene encodes for a DNA-binding 
phosphoprotein that prevents progress past the G1-phase of the cell cycle if 
DNA damage has occurred [70]. It is also characterized as a transcription factor, 
activating and promoting expression of genes involved in growth inhibition. The 
protein p53 is involved in several essential cell functions including control of the 
cell cycle, DNA repair and apoptosis, and thus is called the “guardian of the 
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genome”. The half-life of wild type p53 protein and mutant p53 protein is 
approximately 20 minutes and 24 hours, respectively. The extended half-life of 
mutant p53 allows it to accumulate in the nucleus and be over-expressed in 
tumours [70]. Mutations of p53 are found in more than 50% of all human 
cancers and in more than 75% of colorectal adenocarcinomas [69]. 
It is debated whether the gene “deleted in colorectal carcinogenesis” (DCC) is a 
candidate tumoursuppressor gene. The DCC gene is deleted in more than 70% 
of colorectal carcinomas [71]. A second candidate tumour-suppressor gene, 
DPC4/Smad4, located in the same region on 18q21, is deleted in up to a third 
of the cases. The protein family SMAD are intracellular proteins that mediate 
the effects of signaling from extracellular transforming growth factor beta (TGF-
U) and TGF-U-related factors [72]. 
Microsatellite instability (MSI) is explained by defects in DNA mismatch repair 
(MMR) genes, encoding proteins involved in recognition and repair of single 
base lesions and larger strand slippage mismatches in DNA replication. In 
sporadic colorectal cancer MSI usually arises due to epigenetic silencing of the 
DNA mismatch repair gene MutL homologue 1 MLH1 by methylation of cytosine 
and guanine residues in CpG-rich promoter regions [73], which prevents the 
gene-regions from being transcribed. MSI causes the Lynch syndrome primarily 
by a germline mutation in the mismatch repair genes MutS homologue 2 
(MSH2) and MLH1. The life time risk of developing colorectal cancer is up to 
75% higher in children with Lynch syndrome compared with the general 
population. Approximately 70% of large bowel tumours in patients with Lynch 
syndrome arise in the right/proximal colon [74]. 
The two pathways in the adenoma-carcinoma sequence, involving the 
chromosomal instability and microsatellite instability, seems well characterized. 
However, recent molecular studies have shown that colorectal carcinogenesis is 
not necessarily clearly divided into these two pathways, and may include other 
routes like the transforming growth factor beta (TGF-U)/SMAD-pathway, the 
serrated pathway and the epigenetic pathway. The TGF-U family are known 
inhibitors of gastrointestinal epithelial cell proliferation. Under normal 
circumstances TGF-U are involved in phosphorylation of two cytoplasmic 
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proteins, Smad2 and Smad3, following a formation of a heteromeric complex 
with Smad4. This complex translocates to the nucleus where it induces TGF-U 
target gene transcription [75]. Disruption of the TGF-U/Smad signalling 
pathway causes up-regulation of epithelial cell proliferation which may lead to 
tumorigenesis. 
Smad2 and Smad4 are frequently inactivated in human cancers confirming their 
function as tumor suppressor genes [72]. The serrated pathway is characterized 
by early involvement of oncogenic mutations in the BRAF or KRAS genes and 
excess CpG island methylation. K-Ras and B-Raf are participants in a pathway 
regulating cell growth, differentiation and apoptosis (the MAPK-ERK pathway) 
[76]. 
Recently, a wealth of studies has implicated alterations in the epigenome, as 
also being important in cancer formation [77]. Epigenetics refers to heritable 
modifications to DNA that regulate gene expression without involvement of 
change in the DNA sequence. These modifications are amendments or chemical 
modifications to the DNA that includes global hypomethylation at repititive 
sequences in satellite or pericentromeric regions, focal hypermethylation at CpG 
islands, histone modifications by deacetylation and methylation of amino acids 
in the histone tails (reviewed in [78]) and DNA alkylation by methylation of 
guanine [79]. A new aspect of recent studies of epigenetic alterations in cancer 
is the observation that some genes that are involved in DNA repair (mismatch 
repair) are commonly found to be aberrantly methylated in the early stages of 
tumors [80]. 
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5. Aim of the study 
 
In our previous studies on paraneoplastic polydermatomyositis (81-83), we 
screened a small series of skeletal muscle biopsies from asymptomatic patients 
at early diagnosis for CCR, identifying an unexpected population of muscle 
fibers with nuclei misplaced from their physiological position (82). Aim of the 
present study is to confirm this observation in a larger group of CCR patients, 
also verifying whether these features are associated to the clinical-serological 
profile at diagnosis and during the follow-up, possibly providing new diagnostic 
and prognostic biomarkers for CCR and cancer-associated muscle wasting and 
explaining molecular pathways responsible of these cellular alterations. 
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 6. Materials and Methods 
6.1 Patients and Controls 
Patients undergoing laparoscopic or laparotomic resection for colorectal cancer, 
referring to the Coloproctological Surgery Unit of Padua University between July 
2008 and August 2010, were selected within endoscopic screening protocols 
and recruited for the study. 
Inclusion criteria were: early diagnosis of colorectal cancer,  no neoadjuvant 
treatments, no weight loss or other clinical signs of myopathy, no previous 
cancers. Exclusion criteria were: neoadjuvant treatment; previous neoplasms, 
systemic or radiant treatment before surgery, a weight loss >10% (with respect 
to habitual weight during the last 6 months); clinical signs of myopathy, 
presence of muscle pain, weakness or fatigue. 
Patients undergoing surgery for benign, non-inflammatory conditions were also 
recruited as a control group. All patients included in the study signed an 
informed consent.  
Demographic parameters (age, gender), Body Mass Index (BMI), clinical details 
(including previous surgeries, treatment with drugs known to induce myopathy, 
and concomitant diseases) were recorded at diagnosis and during the follow-up.  
Follow-up was performed according to Institute protocols: in the first two years 
clinical and serological evaluations were performed every six months, also with 
chest X-Ray, colonoscopy and Liver ultrasonography or CT-scan. Starting from 
the third year of follow-up clinical, serological and radiological evaluations were 
performed annually, in absence of cancer relapse.  
Operative time, surgical technique, site of the tumor and the 
anatomopathological characteristics of the surgically removed neoplasia (PTNM 
classification, tumor pattern; mitotic index, necrosis, lymphomonocytic 
infiltrate, vascular and perineural invasion, grading) were recorded.  
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6.2 Skeletal muscle biopsies and blood samplings  
At the beginning of surgery all patients and controls underwent open biopsy of 
the rectus abdominis muscle. All biopsies were immediately frozen and stored in 
liquid nitrogen until use. 
A venous blood sample was taken before surgery, collected serum was frozen in 
500 microliters aliquots and stored at -80°C until use.  
6.3 Serological analyses 
Peripheral red and white blood cell counts, and biochemical parameters, 
including transthyretin, serum albumin, C reactive protein (CRP), muscle creatin 
kinase (CK) and cancer associated biomarkers (CEA, CA 19.9, AFP) were 
measured using routine laboratory methods. 
6.4 Histological and histochemical analyses 
Serial cross sections (8 µm thickness) from frozen muscle biopsies were 
mounted on polysine™ glass slides, air-dried and used for further analyses. For 
morphometric analysis the mean muscle fiber diameter was evaluated in 
Hematoxilin and Eosin (HE) stained cross sections using Scion Image software 
for Windows, version Beta 4.0.2, (2000 Scion Corporation, Inc.; 
www.scioncorp.com). 
Slides images were acquired using a Zeiss microscope connected to a Leica DC 
300F camera at low magnification; identical conditions were used to acquire 
reference ruler images. On the acquired images, nuclei were counted and 
categorized as located inside or at the periphery of the muscle fiber, within the 
extracellular matrix. The number of muscle fibers with internally located nuclei 
was expressed as the percentage of the number of abnormally nucleated 
fibers/number of total fibers of biopsy’s area. 
6.5 Immunofluorescence analyses 
For immunofluorescence analyses in order to detect fast and slow myosin heavy 
chains proteins, regenerating muscle fibers (MHC-emb and N-CAM), nuclei 
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expressing marker of muscle stem cells (Pax7), or plasma membrane associated 
protein (laminin), unfixed sections were labelled either for 1 hour at room 
temperature (RT) or overnight at 4°C, with mouse monoclonal anti-embryonic, 
fast or slow myosin heavy chain antibodies (Novocastra, Newcastle-upon-Tyne, 
U.K.), rabbit polyclonal anti-N-CAM antibody (Chemicon, Italy), anti-Pax7 mouse 
monoclonal antibody (DSHB, Iowa), or anti-laminin rabbit polyclonal antibody 
(Sigma, Italy) 1:100 diluted in PBS, respectively. Sections were then incubated 
for 1 hour at RT with Cy3 or Alexa Fluor® 488 dye conjugated antibodies 
against rabbit (Chemicon, Italy) or mouse IgG (Life technologies, Italy). 
Sections were then  mounted on glass slides using ProLong Gold antifade 
reagent with DAPI (Life Technologies).  
On the acquired images the number of MHC-emb and N-CAM positive muscle 
fibers were counted and expressed as the number of positive fibers per mm2 of 
total biopsy’s area (each mm2 corresponds approximately to 500 muscle fibers). 
 
6.6 Western Blot 
Antibodies against LC3 (rabbit, polyclonal,1:1,000 in 2.5% milk in Tris-Buffered 
Saline Tween 20 (TBST);Novus Biologicals), p62 (mouse, monoclonal, 1:1,000 
in 2.5% milk in TBST; BD Biosciences), and α-tubulin (mouse, monoclonal, 
1:1,000 in 2.5% milk TBST; Sigma) were used. The ECL Advance Western 
Blotting Detection Kit (Amersham Biosciences) was used for signal detection. 
 
6.7 Statistical analysis 
Continuous variables have been compared with non-parametric Wilcoxon test 
with exspression of Median value and Interquartile Range (IQR). Categorical 
variables have been compared with Fisher exact test. Association between 
continuous variables was assesed with Spearman’s Rho coefficient. Statistical 
significance was defined as p < 0,05. All statistical analyses were performed 
with SAS 9.1.  
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 7. Results 
We screened rectus abdominis muscle biopsies from 50 weight stable, non 
cachetic  patients affected with CCR at diagnosis and from 25 healthy subjects 
undergoing surgery for benign non-inflammatory conditions as controls (Tab. 
3). 
 
Table 3. Demographic characteristics of the recruited patients; site and TNM 
classification of resected specimens from CCR patients. 
 
Controls (n=25) 
 Median age (IQR) 61 (35-66) 
 Sex (M:F) 18:7 
CCR patients (n=50) 
 Median age (IQR) 67 (61-70) 
 Sex (M:F) 28:22 
Site of neoplasm  No. (%) 
 Right colon 8 (16) 
 Left colon 28 (56) 
 Rectum 13 (26) 
 Colon-rectum 1 (2)   
PTNM classification No. (%) 
 pTis/T1/T2 23 (46) 
 pT3/T4 27 (54) 
 pN0 36 (72) 
 pN1-2 14 (28) 
 pM0 47 (94) 
 pM1 3 (6) 
 
F, female; M, male; IQR, interquartile range; 
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In serial sections, muscle fibers with nuclei mispositioned in the cytoplasm were 
observed (Fig.5)  and nuclei ultrastructure was confirmed by Electron 
Microscopy (Fig.6). 
 
 
 
 
 
 
 
 
 
Fig.5 Muscle sections showed fibers with nuclei placed at sarcolemma and between 
myofibrills (arrowed in black).  
 
 
Fig.6  Nuclei ultrastructures were confirmed by Electron Microscopy. 
 
Both, at univariate and multivariate analyses, the percentage of fibers with 
internal nuclei was significantly higher in CCR patients compared to controls 
(Fig.7).  
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Fig. 7 The percentage of fibers with internally located nuclei was significantly higher in 
CCR patients compared to controls 
 
Internal nuclei were negative for CD45 (leukocyte common antigen) (Fig.8) and 
Pax7, a nuclear transcription factor, expressed by quiescent muscle stem cells 
(satellite cells) that become activated contributing to postnatal muscle growth 
and repair (Fig.9).  
 
Fig.8 Seldom immuno-inflammatory cells were detected inside small vessels (brown 
stained), while misplaced nuclei were negative (white arrowed). 
 
 
Fig.9 In CCR patients some muscle stem cells (green arrowed) physiologically 
positioned at peryphery were found, but not inside the fiber. 
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Some fibers expressing the embryonic isoform of Myosin Heavy Chain (MHC-
emb) and Neural Cell Adhesion Molecule (N-CAM), two biomarkers of muscle 
regeneration, were identified at higher percentage in CCR patients compared to 
controls, even though not significantly for MHC-emb, while significantly for N-
CAM.  
  
                                                                Controls          CCR Patients p  
 
Fiber diameter (mean±SD, µm)                        50,0±7,9         53,0±8,7       n.s.  
Abnormally nucleated fibers (median±SD, %)    4,0±2,5           15,2±11,8         0,0002 
MHC-emb positive fibers (mean, %)                  11,0                12,0       n.s. 
N-CAM positive fibers (mean, %)                      16,0                40,0         0,04 
  
MHC-emb embryonic myosin heavy chain; N-CAM neural cell adhesion molecule; p statistical 
significance at univariate analyses; n.s. not significant; SD standard deviation. Significant 
values are indicated in bold.  
Tab.4 Histopathological features of rectus abdominis muscle biopsies. 
 
However, this significance was lost at multivariate analyses normalized by age. 
Atrophy of muscle fibers in CCR biopsies, wasn’t observed, and no correlation 
was found between regenerating and internally nucleated fibers. At univariate 
analysis, the percentage of internally nucleated fibers was inversely correlated 
either with lymph-node metastasis or with the number of metastatic lymph 
nodes at diagnosis (ρ=-0.30; p=0.03). This significant correlation was 
confirmed also at multivariate analysis (p=0.02) (Tab.5). 
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  Abnormally Nucleated fibers (%) p 
 Median (IQR) 
 
Age (ρ) -0,14  0,33   
Sex    M  16,0 (8,7-22,6)  0,11 
         F  9,1 (5,1-18,9)   
BMI (ρ)  0,21  0,14 
pT    1-2  15,0 (6,0-20,0)  0,96 
        3-4  12,6 (6,6-21,2)   
pN    0  15,5 (8,2-22,6)  0,05 
        1-2  7,1 (4,6-18,3)   
N+ (ρ)       -0,30  0,03 
pM    0  12,8 (6,0-21,5)  0,95 
        1  19 (10,9-19,7)   
Perivascular Invasion        
        Present 12,8 (8,4-21,0)   0,13 
        Absent 6,6 (4,9-18,8)   
  
Tab 5. Correlation between abnormally nucleated muscle fibers (%) in CCR patients 
and clinical and phenotypical characteristics of the tumor (BMI, Body Mass Index; IQR, 
interquartile range. Significant values are indicated in bold). 
Preoperative serum levels of cancer-associated biomarkers CEA, CA19.9 and 
AFP, C reactive protein (CRP) and muscle creatine kinase enzyme (CK) were 
above the normal range in some CCR patients, with no correlation with the 
percentage of abnormally nucleated or regenerating fibers. In the prevalence of 
CCR patients, preoperative serum levels of transthyretin and albumin were 
below the normal range, with mean values significantly lower compared to 
controls (albumin: 34.82 ± 5.8 g/L vs 45.2 ± 5.3, p< 0.01; transthyretin: 
174.38±57.86 mg/L vs 264.00±69.73, p<0.001), but not in correlation with the 
percentage of internally nucleated fibers (Fig.10). 
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Fig.10 Preoperative serum levels of transthyretin and albumin were significantly lower 
in CCR patients. 
 
Molecular analyses showed a modulation  of  LC3  lipidation  and an 
accumulation  of  p62  in skeletal muscle biopsies from  CCR patients at 
Western Blot; densitometry of p62 levels showed significant accumulation of 
p62 in tumor patients compared to controls (p < 0.05), with higher risk of 
relapse even if in absence of statistical significance (Fig.11). 
 
Fig.11 Modulation of autophagy flux in skeletal muscle of colorectal cancer patients. 
Mean follow-up of CCR patients was 38±12 months: deceases occurred in 18% 
(9/50) and cancer recurrences in 32% (16/50). 50% of CCR patients (UICC 
Stage III-IV) was treated with adjuvant chemotherapy. No significant 
differences between the percentage of internally nucleated fibers, and 
preoperative serological parameters between treated and untreated CCR 
patients, were observed (Tab.6). 
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                                                                           CHT             No CHT       p 
                                                                               (n=25)         (n=25)   
 
Myofiber diameter (mean±SD, µm)                         55,1±8,3       51,0±8,7       n.s. 
Abnormally nucleated fibers (mean±SD, %)             15,0±10,4     16,4±12,8      n.s. 
Transthyretin (mean±SD, mg/L)                              182,7±51,2   171,6±57,5     n.s 
Albumin (mean±SD, g/L)                                        41,1±4,6       41,4±4,2      n.s. 
  
CHT chemotherapy; SD standard deviation.  
Tab.6 Histopathological features and serological markers of protein turnover in CCR 
patients treated and not treated with neo-adjuvant neo-adjuvant chemotherapy after 
surgery. 
Cancer relapse was significantly correlated with lymph-node metastasis, and 
serum levels of transthyretin and albumin, as well as the percentage of 
internally nucleated myofibers at diagnosis were lower in those patients with 
cancer recurrence, compared to those without relapse, even though not 
significantly (Tab.7). None of the CCR patients developed cachexia during the 
follow-up. 
                                                                       Relapse           No Relapse 
                                                                            (n=16)             (n=34)              p  
 
Abnormally nucleated fibers (mean±SD, %)         13,2±10,4          16,2±11,5         0,42 
Lymph-node metastasis (mean, %)                     46                      19  0,02 
Transthyretin (mean±SD, mg/L)                         156,5±44,2         190,6±57,2  0,08 
Albumin (mean±SD, g/L)                                   33,1±6,5            36,1±5,6  0,16 
  
SD standard deviation. Significant values are indicated in bold.  
Tab.7 Correlation between clinical outcome and abnormally nucleated fibers and 
serological markers of protein turnover in CCR patients. 
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 8. Discussion 
Colorectal cancer is the second cause of cancer death in Europe and the third 
most often diagnosed neoplasia in the United States [84].  
In our previous studies we observed a subclinical myopathy in a small group of 
patients affected with newly diagnosed colorectal cancer [81-83]. Surprisingly, 
the observed myopathic features were never been observed in the skeletal 
muscle of patients at this stage of disease, and were very similar to those 
detected in patients affected with cancer-associated myositis [83]. 
This preliminary and unexpected observation raised the question whether these 
morphological changes of the skeletal muscle in cancer patients were 
associated to the clinical and serological profile of the patients, possibly 
providing new diagnostic and prognostic markers of disease. 
In order to address this question, we collected additional skeletal muscle 
biopsies from the rectus abdominis of patients affected with colorectal cancer at 
diagnosis undergoing surgery for tumor colorectal resection and subjects 
affected with benign non-inflammatory conditions as controls.  
In the skeletal muscle from cancer patients, a significantly higher percentage of 
myofibers with abnormal distribution of the myonuclei and of regenerating 
myofibers expressing the MHC-emb and N-CAM was found in comparison to 
control biopsies (Tab.4). In particular, up to the 60% of the patients had a 
percentage of internally nucleated myofibers higher than the reported normal 
value (5%) [81,85-86]. 
Skeletal muscle during ageing undergoes several morphological changes 
characterized by muscle fiber atrophy, mainly of the fast type fibers, changes in 
fiber type distribution with a shift to a slower contractile phenotype, significant 
increase of fat and connective tissues, and motor unit remodeling documented 
by the presence of type grouping [87-89]. These age-related changes in muscle 
histology are predominantly observed starting from the 50 years of the subject, 
and are associated with a decrease in muscle force and contractile properties  
[90-91]. Beside the median age of 67 years of the cancer patients enrolled in 
the present study, in the skeletal muscle from these subjects we did not 
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observed the classical histopathological features of ageing except for the 
presence of slow type grouping as a typical sign of re-innervation in response to 
denervation events. 
The shifting towards slow type fiber distribution in aged skeletal muscle is a 
general issue [89-93], but in the skeletal muscles from these group of cancer 
patients we observed a higher percentage of fast type myofibers compared to 
controls, even though the difference was not statistically significant (p= 0.06). 
The interesting point is that the abnormally nucleated myofibers were 
predominantly of fast type, indicating that this phenomenon is restricted to a 
specific type of muscle fibers.  
Even if the age of our patients could be a critical point because of the 
associated muscle histopathology, no correlation was found between the 
percentage of internally nucleated myofibers and the age of the patients, both 
at univariate and multivariate analyses (Tab.5). Beside this, the multivariate 
analyses normalized by age, showed that the percentage of N-CAM positive 
myofibers was not significantly higher in patients compared to controls, 
indicating that this feature is more closely related to the age of the patients, 
reasonably as results of the denervation events associated to the age-related 
motor unit remodeling [86-89,92,93]. Both denervated and regenerating 
myofibers overexpress N-CAM molecule. In the skeletal muscles from our 
cancer patients, features of denervation and muscle fiber regeneration have 
been observed, but these aspects were not observed in association with the 
abnormal redistribution of myonuclei within the muscle fibers, indicating that 
these seem to be independent phenomena. 
The negative expression of muscle stem cell marker by the misplaced nuclei, 
and the absence of correlation with regeneration events, indicates that they are 
post mitotic nuclei in mature and adult muscle fibers (Fig. 9) [83]. In the 
absence of local and systemic inflammation, this phenomenon can possibly 
occur in response to factors released by tumor microenvironment.   
The intriguing inverse correlation observed between the percentage of 
abnormally nucleated fibers and lymph-nodes metastasis at diagnosis (Tab.5), 
indicate that these features could represent an adaptive response or an initial 
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defense mechanism of skeletal muscle to the onset and spreading of the tumor. 
This hypothesis is also supported by the observation that patients in which the 
percentage of fibers with nuclear abnormalities was higher at diagnosis, had 
better prognosis in terms of cancer relapse. Furthermore, recent studies 
focused on the contribution of autophagy in muscle wasting in cancer patients 
[94-99]; in particular, an activation of autophagy, probably induced by TNF-α, 
with an impairment of autophagic flux, has been demonstrated [96-98], with a 
relationship between tumorigenesis, cachexia and high levels of p62, a typical 
marker of autophagy induction [99]. According to these findings we 
demonstrated in C26-bearing cachectic mice an accumulation of p62, and these 
significant higher accumulation has been confirmed in skeletal muscle biopsies 
from cancer patients compared to controls (Fig. 11).  
Furthermore, we have seen that promoting autophagy with exercise and two 
different drugs could ameliorate muscle homeostasis in cachectic mice, 
suggesting that exercise, as well as  autophagy triggering drugs, could reveal a 
potential use in order to improve cancer cachexia, as described by some 
authors [100-101]. 
Transthyretin has been described as a prognostic marker of cancer relapse in 
patients affected with non-small-cell lung and CCR [102-103]; in line with these 
data, in our study patients who developed relapse, had lower preoperative 
levels of transthyretin compared to those without relapse, in trend of statistical 
significance.  
These findings need more exhaustive investigations focused on the underlying 
molecular mechanisms, but they raise new perspectives on skeletal muscle 
physiopathology in CCR: the muscle can be not only a pathological target of the 
disease, but also as a tissue responding to the onset of the disease, 
contributing with many other factors, to the final outcome towards healing or 
dissemination of cancer.  
We can conclude that in CCR patients at diagnosis, skeletal muscle fibers show 
nuclear abnormalities that seems to be associated to a better prognosis, and by 
altered protein turnover biomarkers, with an impairment in the physiological 
autophagic flux, which seem to be correlated with poor prognosis, defining 
subgroups of patients that could need different follow-up programs. 
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